{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:59:46Z","timestamp":1794909586653,"version":"4.9.1"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":297,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA232563"],"award-info":[{"award-number":["U01 CA232563"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA232563-S2"],"award-info":[{"award-number":["U01 CA232563-S2"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA232486"],"award-info":[{"award-number":["U01 CA232486"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA243072"],"award-info":[{"award-number":["U01 CA243072"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K99\/R00 CA212302"],"award-info":[{"award-number":["K99\/R00 CA212302"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA009615"],"award-info":[{"award-number":["T32 CA009615"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA115299"],"award-info":[{"award-number":["T32 CA115299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180683P1"],"award-info":[{"award-number":["CA180683P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["ASPIRE Oncology\/Hematology"],"award-info":[{"award-number":["ASPIRE Oncology\/Hematology"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT-27-17"],"award-info":[{"award-number":["SU2C-AACR-DT-27-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["T2018-014"],"award-info":[{"award-number":["T2018-014"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24 CA114766"],"award-info":[{"award-number":["U24 CA114766"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA196173"],"award-info":[{"award-number":["U24CA196173"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Downregulation of surface epitopes causes postimmunotherapy relapses in B-lymphoblastic leukemia (B-ALL). Here we demonstrate that mRNA encoding CD22 undergoes aberrant splicing in B-ALL. We describe the plasma membrane\u2013bound CD22 \u0394ex5\u20136 splice isoform, which is resistant to chimeric antigen receptor (CAR) T cells targeting the third immunoglobulin-like domain of CD22. We also describe splice variants skipping the AUG-containing exon 2 and failing to produce any identifiable protein, thereby defining an event that is rate limiting for epitope presentation. Indeed, forcing exon 2 skipping with morpholino oligonucleotides reduced CD22 protein expression and conferred resistance to the CD22-directed antibody\u2013drug conjugate inotuzumab ozogamicin in vitro. Furthermore, among inotuzumab-treated pediatric patients with B-ALL, we identified one nonresponder in whose leukemic blasts \u0394ex2 isoforms comprised the majority of CD22 transcripts. In a second patient, a sharp reduction in CD22 protein levels during relapse was driven entirely by increased CD22 exon 2 skipping. Thus, dysregulated CD22 splicing is a major mechanism of epitope downregulation and ensuing resistance to immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The mechanism(s) underlying downregulation of surface CD22 following CD22-directed immunotherapy remains underexplored. Our biochemical and correlative studies demonstrate that in B-ALL, CD22 expression levels are controlled by inclusion\/skipping of CD22 exon 2. Thus, aberrant splicing of CD22 is an important driver\/biomarker of de novo and acquired resistance to CD22-directed immunotherapies.<\/jats:p>\n                    <jats:p>See the interview with Sarah K. Tasian, MD, and Andrei Thomas-Tikhonenko, PhD, corecipients of the 2024 Blood Cancer Discovery Award for Outstanding Journal Article: https:\/\/vimeo.com\/992990779<\/jats:p>\n                    <jats:p>See related commentary by Bourcier and Abdel-Wahab, p. 87.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 85.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-21-0087","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T10:35:14Z","timestamp":1636972514000},"page":"103-115","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies"],"prefix":"10.1158","volume":"3","author":[{"given":"Sisi","family":"Zheng","sequence":"first","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gillespie","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-666X","authenticated-orcid":false,"given":"Ammar S.","family":"Naqvi","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"3Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3111","authenticated-orcid":false,"given":"Katharina E.","family":"Hayer","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"3Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Ang","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-8113","authenticated-orcid":false,"given":"Manuel","family":"Torres-Diz","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Quesnel-Valli\u00e8res","sequence":"additional","affiliation":[{"name":"4Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"5Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hottman","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asen","family":"Bagashev","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chukinas","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schmidt","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Asnani","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Shraim","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"3Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-4610","authenticated-orcid":false,"given":"Deanne M.","family":"Taylor","sequence":"additional","affiliation":[{"name":"3Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"6Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-4321","authenticated-orcid":false,"given":"Maureen M.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"7Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Singh","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen W.","family":"Lynch","sequence":"additional","affiliation":[{"name":"5Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-5048","authenticated-orcid":false,"given":"Yoseph","family":"Barash","sequence":"additional","affiliation":[{"name":"4Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"6Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2206","authenticated-orcid":false,"given":"Andrei","family":"Thomas-Tikhonenko","sequence":"additional","affiliation":[{"name":"1Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"2Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"6Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"9Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"2025112416470893200_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112416470893200_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2016","journal-title":"Leukemia"},{"key":"2025112416470893200_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025112416470893200_bib4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2025112416470893200_bib5","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2025112416470893200_bib6","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2025112416470893200_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"key":"2025112416470893200_bib8","doi-asserted-by":"crossref","first-page":"e00383","DOI":"10.1128\/MCB.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"key":"2025112416470893200_bib9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2025112416470893200_bib10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"2025112416470893200_bib11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2025112416470893200_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/PPO.0000000000000381","article-title":"Escape from ALL-CARTaz: leukemia immunoediting in the age of chimeric antigen receptors","volume":"25","author":"Zheng","year":"2019","journal-title":"Cancer J"},{"key":"2025112416470893200_bib13","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112416470893200_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112416470893200_bib15","first-page":"e132","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","author":"McNeer","year":"2020","journal-title":"ASCO Educ Book"},{"key":"2025112416470893200_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Ereno-Orbea","year":"2017","journal-title":"Nat Commun"},{"key":"2025112416470893200_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.coi.2005.03.005","article-title":"The role of CD22 and other inhibitory co-receptors in B-cell activation","volume":"17","author":"Nitschke","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"2025112416470893200_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2025112416470893200_bib19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"key":"2025112416470893200_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2019-128977","article-title":"A phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R\/R) CD22+ B-acute lymphoblastic leukemia (B-ALL): results from Children's Oncology Group protocol AALL1621","volume":"134","author":"O'Brien","year":"2019","journal-title":"Blood"},{"key":"2025112416470893200_bib21","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"key":"2025112416470893200_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"2025112416470893200_bib23","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1200\/JCO.2020.38.15_suppl.10519","article-title":"Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): results from central CD22 testing on the Children's Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL)","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112416470893200_bib24","doi-asserted-by":"crossref","first-page":"16852","DOI":"10.1073\/pnas.1007896107","article-title":"CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia","volume":"107","author":"Uckun","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112416470893200_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.2011.08901.x","article-title":"CD22 exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia","volume":"156","author":"Ma","year":"2012","journal-title":"Br J Haematol"},{"key":"2025112416470893200_bib26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/pbc.24420","article-title":"Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia","volume":"60","author":"Hunger","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2025112416470893200_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cels.2016.10.021","article-title":"The BLUEPRINT data analysis portal","volume":"3","author":"Fernandez","year":"2016","journal-title":"Cell Syst"},{"key":"2025112416470893200_bib28","doi-asserted-by":"crossref","first-page":"e11752","DOI":"10.7554\/eLife.11752","article-title":"A new view of transcriptome complexity and regulation through the lens of local splicing variations","volume":"5","author":"Vaquero-Garcia","year":"2016","journal-title":"eLife"},{"key":"2025112416470893200_bib29","first-page":"11357","article-title":"Aberrant splicing in B-cell acute lymphoblastic leukemia","volume":"46","author":"Black","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2025112416470893200_bib30","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/s41467-019-11272-z","article-title":"A comprehensive examination of Nanopore native RNA sequencing for characterization of complex transcriptomes","volume":"10","author":"Soneson","year":"2019","journal-title":"Nat Commun"},{"key":"2025112416470893200_bib31","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1172\/JCI134424","article-title":"Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL","volume":"130","author":"Hurtz","year":"2020","journal-title":"J Clin Invest"},{"key":"2025112416470893200_bib32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2019.00699","article-title":"N-linked glycosylation regulates CD22 organization and function","volume":"10","author":"Wasim","year":"2019","journal-title":"Front Immunol"},{"key":"2025112416470893200_bib33","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood-2012-12-473090","article-title":"The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop","volume":"122","author":"Psathas","year":"2013","journal-title":"Blood"},{"key":"2025112416470893200_bib34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI45851","article-title":"CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis","volume":"122","author":"Chung","year":"2012","journal-title":"J Clin Invest"},{"key":"2025112416470893200_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"2025112416470893200_bib36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2012-12-474239","article-title":"CAReful epitope selection matters","volume":"121","author":"Handgretinger","year":"2013","journal-title":"Blood"},{"key":"2025112416470893200_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.1.3.8113","article-title":"Identification and characterization of fully human anti-CD22 monoclonal antibodies","volume":"1","author":"Xiao","year":"2009","journal-title":"MAbs"},{"key":"2025112416470893200_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2025112416470893200_bib39","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025112416470893200_bib40","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"},{"key":"2025112416470893200_bib41","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025112416470893200_bib42","doi-asserted-by":"crossref","first-page":"e28112","DOI":"10.1002\/pbc.28112","article-title":"Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia","volume":"67","author":"Shah","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2025112416470893200_bib43","doi-asserted-by":"crossref","first-page":"e151627","DOI":"10.1172\/JCI151627","article-title":"RNA-binding proteins of COSMIC importance in cancer","volume":"131","author":"Choi","year":"2021","journal-title":"J Clin Invest"},{"key":"2025112416470893200_bib44","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's Oncology Group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112416470893200_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"2025112416470893200_bib46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"key":"2025112416470893200_bib47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025112416470893200_bib48","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/bioinformatics\/btx100","article-title":"BCFtools\/csq: haplotype-aware variant consequences","volume":"33","author":"Danecek","year":"2017","journal-title":"Bioinformatics"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/2\/103\/3483988\/103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/2\/103\/3483988\/103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:47:23Z","timestamp":1764020843000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/3\/2\/103\/681790\/Modulation-of-CD22-Protein-Expression-in-Childhood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,4]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0087","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.22544531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544525.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544528.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544534.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544531.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544525","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6550676.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550676","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}